A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs INCB 54828 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Therapeutic Use
- Acronyms FIGHT-203
- Sponsors Incyte Corporation
- 20 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Dec 2019.
- 20 Feb 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Oct 2019.
- 05 Apr 2017 Primary analysis is expected in January 2019 as per trial design presented at the 108th Annual Meeting of the American Association for Cancer Research